ClinicalTrials.gg
CompletedNCT00727857Updated Jul 29, 2011Results posted

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

A Phase 3 interventional study of Pioglitazone and metformin and Pioglitazone in Diabetes Mellitus, sponsored by Takeda. Completed at 77 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-29.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
15th of 122
600 · median 103
Started
2007
with 11 others
Phase 3
31 of 122
1 open now
Registered
43rd of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 12 that started in 2007, is one of 31 in phase 3, and was the 43rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of pioglitazone, twice daily (BID), combined with metformin versus pioglitazone taken alone and metformin taken alone in treating Type 2 Diabetes Mellitus.

Read the detailed description

Pioglitazone hydrochloride (ACTOS®) is a member of a class of oral antidiabetic agents known as thiazolidinediones, which act by reducing insulin resistance. Insulin resistance is a key feature of dysmetabolic syndrome and has been suggested to be the common pathophysiologic basis of both atherosclerosis and type 2 diabetes. Pioglitazone binds to peroxisome proliferator-activated receptors, an effect that is associated with altered transcription of genes capable of influencing carbohydrate and lipid metabolism.

Metformin hydrochloride is an oral antihyperglycemic drug not chemically or pharmacologically related to thiazolidinediones. Metformin is a biguanide, which has been shown to be effective in improving glycemic control in diabetic patients. Metformin inhibits hepatic glucose production, most likely through an inhibition of gluconeogenesis, and its use is associated with an improvement in tissue sensitivity to insulin. In accordance with published algorithms for the use of combination therapy for the treatment of type 2 diabetes, physicians have traditionally combined metformin with other antidiabetic agents.

This study will determine the effect of a fixed-dose combination of metformin with pioglitazone, compared to metformin monotherapy and pioglitazone monotherapy.

Study participation is anticipated to be approximately 6.5 months.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 600 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has type 2 diabetes.
  • Has received no treatment with antidiabetic medication in the 12 weeks prior to Screening, other than short-term use defined as less than or equal to 15 days.
  • A glycosylated greater than or equal to 7.5% and less than or equal to 10.0% at Screening.
  • less than or equal to 45 kg/m2.
  • Has received counseling on lifestyle modification for type 2 diabetes, including diet and exercise.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  • Stable condition as determined by a physician.

Exclusion criteria

Exclusion Criteria

  • Type 1 diabetes.
  • Unstable angina or heart failure of any etiology with functional class III or IV.
  • History of myocardial infarction, cerebrovascular accident, percutaneous coronary intervention, coronary artery bypass graft, or in the 6 months prior to Screening.
  • Male participant has a serum creatinine level greater than or equal to 1.5 mg per dL or female subject has a serum creatinine level greater than or equal to 1.4 mg per dL.
  • Has a triglyceride level greater than 500 mg per dL.
  • Male participant has a level less than 10.5 g per dL or female subject has a hemoglobin level less than 10.0 g per dL.
  • level of greater than 2.5 times the , active liver disease, or jaundice.
  • History of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day) within 2 years prior to Screening.
  • Has been discontinued from a thiazolidinedione or metformin therapy due to lack of efficacy or clinical or laboratory signs of intolerance.
  • Previous history of cancer, other than basal cell or stage 1 squamous cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study medication.
  • History of acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma.
  • Any disease or condition at Screening or Randomization that would compromise safety, might affect , or make it difficult to successfully manage and follow the subject according to the protocol.
  • Currently participating in another study or has participated in an investigational study within 30 days prior to randomization.
  • Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Antidiabetic medications other than study medication
    • Chronically used oral or parenteral
    • Niacin greater than 200 mg per day, including niacin-containing products such as Advicor
    • Chronically used steroid-joint injections
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    Pioglitazone 15 mg /Metformin 850 mg BID

    Drug: Pioglitazone and metformin

  • Active comparator
    Pioglitazone 15 mg BID

    Drug: Pioglitazone

  • Active comparator
    Metformin 850 mg BID

    Drug: Metformin

Interventions

  • DrugPioglitazone and metformin

    Drug pages: Pioglitazone · Metformin

    Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.

    Also known as: ACTOPLUS MET

  • Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.

    Also known as: ACTOS®, AD4833

  • Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.

    Also known as: Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Glycosylated Hemoglobin

    The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit or week 24 and Glycosylated Hemoglobin collected at baseline.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose

    The change between the value of Fasting Plasma Glucose collected at final visit or week 24 and Fasting Plasma Glucose collected at baseline.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Fasting Insulin

    The change between the Fasting Insulin value collected at final visit or week 24 and Fasting Insulin collected at baseline.

    Time frame: Baseline and Week 24

  3. Change From Baseline in Homeostasis Model Assessment - Insulin Resistance

    The change between Homeostasis Model Assessment of Insulin Resistance collected at final visit or week 24 and Homeostasis Model Assessment of Insulin Resistance collected at baseline. Homeostasis Model Assessment measures insulin resistance, calculated by insulin times glucose, divided by a constant (22.5).

    Time frame: Baseline and Week 24

  4. Median Percent Change From Baseline in High Sensitivity C-reactive Protein

    Measurement for High Sensitivity C-reactive Protein was collected at final visit or week 24 and at baseline. Percent change from baseline is calculated as: \[(Week 24 - baseline levels)/baseline\]\*100

    Time frame: Baseline and Week 24

  5. Change From Baseline in Adiponectin

    The change between Adiponectin collected at final visit or week 24 and Adiponectin collected at baseline.

    Time frame: Baseline and Week 24

  6. Change From Baseline in Total Cholesterol

    The change between Total Cholesterol collected at final visit or week 24 and Total Cholesterol collected at baseline.

    Time frame: Baseline and Week 24

  7. Change From Baseline in Low-Density Lipoprotein Cholesterol

    The change between Low-Density Lipoprotein Cholesterol collected at final visit or week 24 and Low-Density Lipoprotein Cholesterol collected at baseline.

    Time frame: Baseline and Week 24

  8. Change From Baseline in High-Density Lipoprotein Cholesterol

    The change between High-Density Lipoprotein Cholesterol collected at final visit or week 24 and High-Density Lipoprotein Cholesterol collected at baseline.

    Time frame: Baseline and Week 24

  9. Change From Baseline in Triglycerides

    The change between Triglycerides collected at final visit or week 24 and Triglycerides collected at baseline.

    Time frame: Baseline and Week 24

  10. Change From Baseline in Mean Low Density Lipoprotein Particle Concentration

    The change between Low Density Lipoprotein particle concentration collected at final visit or week 24 and Low Density Lipoprotein particle concentration collected at baseline.

    Time frame: Baseline and Week 24

  11. Change From Baseline in Mean Low Density Lipoprotein Particle Size

    The change between Low Density Lipoprotein collected at final visit or week 24 and Low Density Lipoprotein collected at baseline.

    Time frame: Baseline and Week 24

  12. Change From Baseline in Large Low Density Lipoprotein (L3) Concentration

    The change between Large Low Density Lipoprotein collected at final visit or week 24 and Large Low Density Lipoprotein collected at baseline.

    Time frame: Baseline and Week 24

  13. Change From Baseline in Intermediate-Density Low Density Lipoprotein Concentration

    The change between Intermediate-Density Low Density Lipoprotein collected at final visit or week 24 and Intermediate-Density Low Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

  14. Change From Baseline in Medium-Small Low Density Lipoprotein Concentration

    The change between Medium-Small Low Density Lipoprotein collected at final visit or week 24 and Medium-Small Low Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

  15. Change From Baseline in Small Low Density Lipoprotein Concentration

    The change between Small Low Density Lipoprotein collected at final visit or week 24 and Small Low Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

  16. Change From Baseline in Very Small Low Density Lipoprotein Concentration

    The change between Very Small Low Density Lipoprotein collected at final visit or week 24 and Very Small Low Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

  17. Change From Baseline in Mean High Density Lipoprotein Particle Concentration

    The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.

    Time frame: Baseline and Week 24

  18. Change From Baseline in Mean High Density Lipoprotein Particle Size

    The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.

    Time frame: Baseline and Week 24

  19. Change From Baseline in Large High Density Lipoprotein (H4+H5) Concentration

    The change between Large High Density Lipoprotein collected at final visit or week 24 and Large High Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

  20. Change From Baseline in Intermediate-Medium High Density Lipoprotein (H3) Concentration

    The change between Intermediate-Medium High Density Lipoprotein collected at final visit or week 24 and Intermediate-Medium High Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

  21. Change From Baseline in Small High Density Lipoprotein (H1+H2) Concentration

    The change between Small High Density Lipoprotein collected at final visit or week 24 and Small High Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

  22. Change From Baseline in Mean Very Low Density Lipoprotein Particle Concentration

    The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.

    Time frame: Baseline and Week 24

  23. Change From Baseline in Mean Very Low Density Lipoprotein Particle Size

    The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.

    Time frame: Baseline and Week 24

  24. Change From Baseline in Large-Chylomicrons Very Low Density Lipoprotein Concentration

    The change between Large-Chylomicrons Very Low Density Lipoprotein collected at final visit or week 24 and Large-Chylomicrons Very Low Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

  25. Change From Baseline in Medium-Intermediate Very Low Density Lipoprotein (V3+V4) Concentration

    The change between Medium-Intermediate Very Low Density Lipoprotein collected at final visit or week 24 and Medium-Intermediate Very Low Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

  26. Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration

    The change between Small Very Low Density Lipoprotein collected at final visit or week 24 and Small Very Low Density Lipoprotein collected at baseline

    Time frame: Baseline and Week 24

08

Results

Posted Mar 9, 2010

Participant flow

Participants were enrolled at 134 investigative sites in the United States (including Puerto Rico), Argentina, Chile, Guatemala, Mexico and Peru from 13 June 2007 to 29 August 2008.

Participant flow — Overall Study
MilestonePioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Started201189210
Completed157125142
Not completed446468

Outcome measures

PrimaryPercent Change From Baseline in Glycosylated Hemoglobin

The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit or week 24 and Glycosylated Hemoglobin collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · percentage of Glycosylated Hemoglobin
Percent Change From Baseline in Glycosylated Hemoglobin
percentage of Glycosylated HemoglobinPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Percent Change From Baseline in Glycosylated Hemoglobin-1.83 ± 0.122-0.96 ± 0.131-0.99 ± 0.120
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): 0.86 · 95% CI 0.51 to 1.22Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): 0.84 · 95% CI 0.50 to 1.18Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.8919 · Mean difference (final values): -0.02 · 95% CI -0.37 to 0.33Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Fasting Plasma Glucose

The change between the value of Fasting Plasma Glucose collected at final visit or week 24 and Fasting Plasma Glucose collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose
mg/dLPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Fasting Plasma Glucose-39.9 ± 3.48-22.2 ± 3.67-24.8 ± 3.42
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.0005 · Mean difference (final values): 17.8 · 95% CI 7.8 to 27.7Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0021 · Mean difference (final values): 15.1 · 95% CI 5.5 to 24.7Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.5981 · Mean difference (final values): -2.6 · 95% CI -12.5 to 7.2Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Fasting Insulin

The change between the Fasting Insulin value collected at final visit or week 24 and Fasting Insulin collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · μIU/mL
Change From Baseline in Fasting Insulin
μIU/mLPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Fasting Insulin-3.91 ± 0.736-3.18 ± 0.812-0.98 ± 0.722
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.5074 · Mean difference (final values): 0.73 · 95% CI -1.43 to 2.88Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0047 · Mean difference (final values): 2.93 · 95% CI 0.90 to 4.95Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0435 · Mean difference (final values): 2.20 · 95% CI 0.06 to 4.33Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Homeostasis Model Assessment - Insulin Resistance

The change between Homeostasis Model Assessment of Insulin Resistance collected at final visit or week 24 and Homeostasis Model Assessment of Insulin Resistance collected at baseline. Homeostasis Model Assessment measures insulin resistance, calculated by insulin times glucose, divided by a constant (22.5).

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · percent of insulin resistance
Change From Baseline in Homeostasis Model Assessment - Insulin Resistance
percent of insulin resistancePioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Homeostasis Model Assessment - Insulin Resistance-2.704 ± 0.4274-2.075 ± 0.4586-1.085 ± 0.4123
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.3158 · Mean difference (final values): 0.629 · 95% CI -0.602 to 1.861Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0067 · Mean difference (final values): 1.619 · 95% CI 0.452 to 2.785Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.1094 · Mean difference (final values): 0.989 · 95% CI -0.223 to 2.201Mean Difference = Pioglitazone - metformin
SecondaryMedian Percent Change From Baseline in High Sensitivity C-reactive Protein

Measurement for High Sensitivity C-reactive Protein was collected at final visit or week 24 and at baseline. Percent change from baseline is calculated as: \[(Week 24 - baseline levels)/baseline\]\*100

Time frame:
Baseline and Week 24
Reported as:
Median · percent
Median Percent Change From Baseline in High Sensitivity C-reactive Protein
percentPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Median Percent Change From Baseline in High Sensitivity C-reactive Protein-36.7 ± 4.6719-34.0 ± 8.1275-26.2 ± 12.5526
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.5963 · Median difference (final values): 4.88 · 95% CI -4.71 to 13.97The estimate of the median percent change from baseline and 95% confidence intervals were based on the Hodges-Lehmann method and the distribution-free confidence interval.
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0265 · Median difference (final values): 12.81 · 95% CI 2.88 to 22.24The estimate of the median percent change from baseline and 95% confidence intervals were based on the Hodges-Lehmann method and the distribution-free confidence interval.
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.1053 · Median difference (final values): 8.33 · 95% CI -1.77 to 18.07The estimate of the median percent change from baseline and 95% confidence intervals were based on the Hodges-Lehmann method and the distribution-free confidence interval.
SecondaryChange From Baseline in Adiponectin

The change between Adiponectin collected at final visit or week 24 and Adiponectin collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mcg/ml
Change From Baseline in Adiponectin
mcg/mlPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Adiponectin7.8 ± 0.559.2 ± 0.61-0.3 ± 0.55
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.0806 · Mean difference (final values): 1.4 · 95% CI -0.2 to 3.1Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -8.1 · 95% CI -9.6 to -6.5Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -9.5 · 95% CI -11.1 to -7.9Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Total Cholesterol

The change between Total Cholesterol collected at final visit or week 24 and Total Cholesterol collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Total Cholesterol
mg/dLPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Total Cholesterol1.06 ± 1.1834.79 ± 1.271-2.72 ± 1.169
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.0324 · Mean difference (final values): 3.73 · 95% CI 0.31 to 7.14Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0233 · Mean difference (final values): -3.78 · 95% CI -7.05 to -0.52Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -7.51 · 95% CI -10.90 to -4.12Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Low-Density Lipoprotein Cholesterol

The change between Low-Density Lipoprotein Cholesterol collected at final visit or week 24 and Low-Density Lipoprotein Cholesterol collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Low-Density Lipoprotein Cholesterol
mg/dLPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Low-Density Lipoprotein Cholesterol1.19 ± 2.0156.08 ± 2.175-1.37 ± 1.998
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.0993 · Mean difference (final values): 4.90 · 95% CI -0.93 to 10.72Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.3670 · Mean difference (final values): -2.56 · 95% CI -8.14 to 3.01Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0119 · Mean difference (final values): -7.46 · 95% CI -13.26 to -1.66Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in High-Density Lipoprotein Cholesterol

The change between High-Density Lipoprotein Cholesterol collected at final visit or week 24 and High-Density Lipoprotein Cholesterol collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in High-Density Lipoprotein Cholesterol
mg/dLPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in High-Density Lipoprotein Cholesterol14.20 ± 1.4409.88 ± 1.5526.09 ± 1.426
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.0423 · Mean difference (final values): -4.31 · 95% CI -8.48 to -0.15Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -8.10 · 95% CI -12.08 to -4.12Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.728 · Mean difference (final values): -3.79 · 95% CI -7.93 to 0.35Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Triglycerides

The change between Triglycerides collected at final visit or week 24 and Triglycerides collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Triglycerides
mg/dLPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Triglycerides-5.95 ± 2.901-5.54 ± 3.107-1.78 ± 2.871
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.9231 · Mean difference (final values): 0.41 · 95% CI -7.94 to 8.76Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.3082 · Mean difference (final values): 4.16 · 95% CI -3.86 to 12.19Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.3753 · Mean difference (final values): 3.75 · 95% CI -4.56 to 12.07Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Mean Low Density Lipoprotein Particle Concentration

The change between Low Density Lipoprotein particle concentration collected at final visit or week 24 and Low Density Lipoprotein particle concentration collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Mean Low Density Lipoprotein Particle Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Mean Low Density Lipoprotein Particle Concentration-240.6 ± 23.50-217.2 ± 25.40-176.4 ± 23.36
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.4999 · Mean difference (final values): 23.4 · 95% CI -44.6 to 91.4Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0531 · Mean difference (final values): 64.2 · 95% CI -0.9 to 129.3Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.2369 · Mean difference (final values): 40.9 · 95% CI -26.9 to 108.7Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Mean Low Density Lipoprotein Particle Size

The change between Low Density Lipoprotein collected at final visit or week 24 and Low Density Lipoprotein collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nm
Change From Baseline in Mean Low Density Lipoprotein Particle Size
nmPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Mean Low Density Lipoprotein Particle Size0.55 ± 0.0490.6 ± 0.0530.2 ± 0.049
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.5023 · Mean difference (final values): 0.05 · 95% CI -0.09 to 0.19Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -0.34 · 95% CI -0.48 to -0.21Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -0.39 · 95% CI -0.53 to -0.25Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Large Low Density Lipoprotein (L3) Concentration

The change between Large Low Density Lipoprotein collected at final visit or week 24 and Large Low Density Lipoprotein collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Large Low Density Lipoprotein (L3) Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Large Low Density Lipoprotein (L3) Concentration96.0 ± 12.53115.7 ± 13.5218.4 ± 12.46
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.2849 · Mean difference (final values): 19.7 · 95% CI -16.5 to 55.9Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -77.6 · 95% CI -112.4 to -42.8Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -97.3 · 95% CI -133.4 to -61.2Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Intermediate-Density Low Density Lipoprotein Concentration

The change between Intermediate-Density Low Density Lipoprotein collected at final visit or week 24 and Intermediate-Density Low Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Intermediate-Density Low Density Lipoprotein Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Intermediate-Density Low Density Lipoprotein Concentration-16.3 ± 3.39-11.0 ± 3.66-17.3 ± 3.37
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.2894 · Mean difference (final values): 5.3 · 95% CI -4.5 to 15.1Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.8463 · Mean difference (final values): -0.9 · 95% CI -10.3 to 8.5Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.2124 · Mean difference (final values): -6.2 · 95% CI -16.0 to 3.6Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Medium-Small Low Density Lipoprotein Concentration

The change between Medium-Small Low Density Lipoprotein collected at final visit or week 24 and Medium-Small Low Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Medium-Small Low Density Lipoprotein Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Medium-Small Low Density Lipoprotein Concentration-63.8 ± 5.95-66.0 ± 6.43-35.3 ± 5.92
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.8040 · Mean difference (final values): -2.2 · 95% CI -19.4 to 15.0Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0008 · Mean difference (final values): 28.5 · 95% CI 12.0 to 45.0Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0005 · Mean difference (final values): 30.6 · 95% CI 13.4 to 47.8Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Small Low Density Lipoprotein Concentration

The change between Small Low Density Lipoprotein collected at final visit or week 24 and Small Low Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Small Low Density Lipoprotein Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Small Low Density Lipoprotein Concentration-319.3 ± 28.06-321.3 ± 30.34-179.0 ± 27.91
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.9604 · Mean difference (final values): -2.1 · 95% CI -83.3 to 79.2Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0004 · Mean difference (final values): 140.3 · 95% CI 62.5 to 218.0Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0006 · Mean difference (final values): 142.3 · 95% CI 61.3 to 223.3Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Very Small Low Density Lipoprotein Concentration

The change between Very Small Low Density Lipoprotein collected at final visit or week 24 and Very Small Low Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Very Small Low Density Lipoprotein Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Very Small Low Density Lipoprotein Concentration-255.5 ± 22.37-255.2 ± 24.18-143.8 ± 22.25
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.9922 · Mean difference (final values): 0.3 · 95% CI -64.4 to 65.1Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0004 · Mean difference (final values): 111.7 · 95% CI 49.7 to 173.7Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0008 · Mean difference (final values): 111.4 · 95% CI 46.8 to 175.9Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Mean High Density Lipoprotein Particle Concentration

The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · μmol/L
Change From Baseline in Mean High Density Lipoprotein Particle Concentration
μmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Mean High Density Lipoprotein Particle Concentration0.28 ± 0.271-0.80 ± 0.2930.62 ± 0.269
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.0072 · Mean difference (final values): -1.08 · 95% CI -1.86 to -0.29Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.3682 · Mean difference (final values): 0.34 · 95% CI -0.41 to 1.10Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0004 · Mean difference (final values): 1.42 · 95% CI 0.64 to 2.20Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Mean High Density Lipoprotein Particle Size

The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nm
Change From Baseline in Mean High Density Lipoprotein Particle Size
nmPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Mean High Density Lipoprotein Particle Size0.15 ± 0.0210.19 ± 0.0220.11 ± 0.021
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.1986 · Mean difference (final values): 0.04 · 95% CI -0.02 to 0.10Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.1487 · Mean difference (final values): -0.04 · 95% CI -0.10 to 0.02Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0076 · Mean difference (final values): -0.08 · 95% CI -0.14 to -0.02Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Large High Density Lipoprotein (H4+H5) Concentration

The change between Large High Density Lipoprotein collected at final visit or week 24 and Large High Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · μmol/L
Change From Baseline in Large High Density Lipoprotein (H4+H5) Concentration
μmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Large High Density Lipoprotein (H4+H5) Concentration0.70 ± 1.801.02 ± 0.1940.52 ± 0.179
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.2384 · Mean difference (final values): 0.31 · 95% CI -0.21 to 0.83Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.4617 · Mean difference (final values): -0.19 · 95% CI -0.69 to 0.31Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0593 · Mean difference (final values): -0.50 · 95% CI -1.02 to 0.02Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Intermediate-Medium High Density Lipoprotein (H3) Concentration

The change between Intermediate-Medium High Density Lipoprotein collected at final visit or week 24 and Intermediate-Medium High Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · μmol/L
Change From Baseline in Intermediate-Medium High Density Lipoprotein (H3) Concentration
μmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Intermediate-Medium High Density Lipoprotein (H3) Concentration1.34 ± 0.2851.62 ± 0.308-0.09 ± 0.283
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.5044 · Mean difference (final values): 0.28 · 95% CI -0.54 to 1.10Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0004 · Mean difference (final values): -1.43 · 95% CI -2.22 to -0.64Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -1.71 · 95% CI -2.53 to -0.89Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Small High Density Lipoprotein (H1+H2) Concentration

The change between Small High Density Lipoprotein collected at final visit or week 24 and Small High Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · μmol/L
Change From Baseline in Small High Density Lipoprotein (H1+H2) Concentration
μmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Small High Density Lipoprotein (H1+H2) Concentration-1.78 ± 0.349-3.41 ± 0.3770.19 ± 0.347
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.0017 · Mean difference (final values): -1.63 · 95% CI -2.64 to -0.62Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): 1.97 · 95% CI 1.01 to 2.94Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): 3.60 · 95% CI 2.59 to 4.61Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Mean Very Low Density Lipoprotein Particle Concentration

The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Mean Very Low Density Lipoprotein Particle Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Mean Very Low Density Lipoprotein Particle Concentration-2.78 ± 2.2040.98 ± 2.381-11.30 ± 2.191
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.2466 · Mean difference (final values): 3.76 · 95% CI -2.61 to 10.14Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0063 · Mean difference (final values): -8.52 · 95% CI -14.63 to -2.42Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0002 · Mean difference (final values): -12.29 · 95% CI -18.65 to -5.93Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Mean Very Low Density Lipoprotein Particle Size

The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nm
Change From Baseline in Mean Very Low Density Lipoprotein Particle Size
nmPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Mean Very Low Density Lipoprotein Particle Size-2.64 ± 0.616-3.79 ± 0.666-0.20 ± 0.612
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.2069 · Mean difference (final values): -1.15 · 95% CI -2.93 to 0.64Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0052 · Mean difference (final values): 2.44 · 95% CI 0.73 to 4.15Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): 3.59 · 95% CI 1.81 to 5.36Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Large-Chylomicrons Very Low Density Lipoprotein Concentration

The change between Large-Chylomicrons Very Low Density Lipoprotein collected at final visit or week 24 and Large-Chylomicrons Very Low Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Large-Chylomicrons Very Low Density Lipoprotein Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Large-Chylomicrons Very Low Density Lipoprotein Concentration-1.71 ± 0.351-1.97 ± 0.379-1.96 ± 0.349
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.6090 · Mean difference (final values): -0.26 · 95% CI -1.28 to 0.75Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.6169 · Mean difference (final values): -0.25 · 95% CI -1.22 to 0.72Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.9740 · Mean difference (final values): 0.02 · 95% CI -0.99 to 1.03Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Medium-Intermediate Very Low Density Lipoprotein (V3+V4) Concentration

The change between Medium-Intermediate Very Low Density Lipoprotein collected at final visit or week 24 and Medium-Intermediate Very Low Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Medium-Intermediate Very Low Density Lipoprotein (V3+V4) Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Medium-Intermediate Very Low Density Lipoprotein (V3+V4) Concentration-4.07 ± 1.434-3.01 ± 1.550-6.48 ± 1.426
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.6150 · Mean difference (final values): 1.06 · 95% CI -3.09 to 5.21Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.2346 · Mean difference (final values): -2.41 · 95% CI -6.38 to 1.57Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.1001 · Mean difference (final values): -3.47 · 95% CI -7.61 to 0.67Mean Difference = Pioglitazone - metformin
SecondaryChange From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration

The change between Small Very Low Density Lipoprotein collected at final visit or week 24 and Small Very Low Density Lipoprotein collected at baseline

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · nmol/L
Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration
nmol/LPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration3.05 ± 1.2495.9 ± 1.350-2.86 ± 1.239
Statistical analysis
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Pioglitazone 15 mg BID · ANCOVA · p = 0.1217 · Mean difference (final values): 2.86 · 95% CI -0.76 to 6.48Mean Difference = Pioglitazone \& metformin - pioglitazone
  • Pioglitazone 15 mg/Metformin 850 mg BID vs Metformin 850 mg BID · ANCOVA · p = 0.0009 · Mean difference (final values): -5.90 · 95% CI -9.36 to -2.44Mean Difference = Pioglitazone \& metformin - metformin
  • Pioglitazone 15 mg BID vs Metformin 850 mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -8.76 · 95% CI -12.36 to -5.16Mean Difference = Pioglitazone - metformin

Adverse events

Collected over Adverse events were summarized by onset date occurring on or after the first dose of double-blind study medication and on or prior to 14 days after the permanent discontinuation of the double-blind study medication.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pioglitazone 15 mg/Metformin 850 mg BID—2/201 (1%)84/201 (41.8%)
Pioglitazone 15 mg BID—3/190 (1.6%)61/190 (32.1%)
Metformin 850 mg BID—5/209 (2.4%)95/209 (45.5%)
Most frequent serious events
Most frequent serious events
EventPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
Acute myocardial infarctionCardiac disorders0/2011/1900/209
HyperglycemiaMetabolism and nutrition disorders0/2011/1900/209
EndometriosisReproductive system and breast disorders0/2011/1900/209
Diverticulum intestinalGastrointestinal disorders1/2010/1900/209
HypoglycemiaMetabolism and nutrition disorders1/2010/1900/209
LeukocytosisBlood and lymphatic system disorders0/2010/1901/209
Cholecystitis chronicHepatobiliary disorders0/2010/1901/209
CellulitisInfections and infestations0/2010/1901/209
DiverticulitisInfections and infestations0/2010/1901/209
FallInjury, poisoning and procedural complications0/2010/1901/209
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BID
DiarrhoeaGastrointestinal disorders18/2015/19032/209
HeadacheNervous system disorders11/2015/19010/209
Urinary tract infectionInfections and infestations6/2015/1909/209
Oedema PeripheralGeneral disorders6/2018/1903/209
Back painMusculoskeletal and connective tissue disorders4/2018/1906/209
PharyngitisInfections and infestations8/2015/1907/209
NasopharyngitisInfections and infestations8/2013/1905/209
BronchitisInfections and infestations5/2017/1903/209
Glycosylated haemoglobinInvestigations2/2017/1907/209
Abdominal painGastrointestinal disorders4/2013/1907/209

Baseline characteristics

Age Continuous
Age Continuous(years)Pioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BIDTotal
Mean54.7 ± 12.2354.0 ± 12.0853.7 ± 12.0054.1 ± 12.09
Sex: Female, Male
Sex: Female, Male(Participants)Pioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BIDTotal
Female111123112346
Male906698254
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BIDTotal
American Indian or Alaska Native26614
Asian35513
Black or African American12131439
Native Hawaiian or Other Pacific Islander0000
White123109124356
Multiracial615661178
Body Mass Index
Body Mass Index(kg/m²)Pioglitazone 15 mg/Metformin 850 mg BIDPioglitazone 15 mg BIDMetformin 850 mg BIDTotal
Mean30.84 ± 5.7431.18 ± 5.5030.83 ± 5.6630.94 ± 5.63
09

Study locations

77 sites
  • Birmingham, Alabama, United States
  • Haleyville, Alabama, United States
  • Montgomery, Alabama, United States
  • Pell City, Alabama, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Anaheim, California, United States
  • Artesia, California, United States
  • Dinuba, California, United States
  • Long Beach, California, United States
  • Los Angeles,, California, United States
  • Norwalk, California, United States
  • Orange, California, United States
  • Santa Ana, California, United States
  • Santa Monica, California, United States
  • Pueblo, Colorado, United States
  • Altamonte Springs, Florida, United States
  • Coral Gables, Florida, United States
  • Hialeah, Florida, United States
  • Miami,, Florida, United States
  • Panama City, Florida, United States
  • Plantation, Florida, United States
  • St Petersburg, Florida, United States
  • St. Cloud, Florida, United States
  • Tampa, Florida, United States
  • Columbus, Georgia, United States
  • Boise, Idaho, United States
  • Coeur d' Alene,, Idaho, United States
  • Chicago, Illinois, United States
  • Flossmoor, Illinois, United States
  • Peoria, Illinois, United States
  • Elkhart, Indiana, United States
  • Shawnee,, Kansas, United States
  • Southfield, Michigan, United States
  • Chesterfield, Missouri, United States
  • Billings, Montana, United States
  • Elizabeth, New Jersey, United States
  • Fayetteville, New York, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Pinehurst, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Perrysburg, Ohio, United States
  • Zanesville, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Eugene, Oregon, United States
  • Fleetwood, Pennsylvania, United States
  • Norristown, Pennsylvania, United States
  • Cranston, Rhode Island, United States
  • Simpsonville,, South Carolina, United States
  • Varnville, South Carolina, United States
  • Fayetteville, Tennessee, United States
  • Corpus Christi, Texas, United States
  • Dallas, Texas, United States
  • El Paso, Texas, United States
  • Houston, Texas, United States
  • McAllen, Texas, United States
  • Mission, Texas, United States
  • New Braunfels, Texas, United States
  • North Richland Hills, Texas, United States
  • San Antonio,, Texas, United States
  • Bountiful, Utah, United States
  • Salt Lake City, Utah, United States
  • Petersburg, Virginia, United States
  • Port Orchard, Washington, United States
  • Spokane, Washington, United States
  • Providencia-Santiago, Chile
  • Temuco, Chile
  • Zapopan, Jalisco, Mexico
  • Monterrey, Nuevo Leon, Mexico
  • Aibonito, Puerto Rico
  • Caguas, Puerto Rico
  • Ciales, Puerto Rico
  • Coto Laurel, Puerto Rico
  • Guayma, Puerto Rico
  • Guaynabo, Puerto Rico
  • Rio Piedras, Puerto Rico
10

References and documents

Publications

  • Perez A, Zhao Z, Jacks R, Spanheimer R. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin. 2009 Dec;25(12):2915-23. doi: 10.1185/03007990903350011. PubMed 19827910 ↗
  • Perez A, Jacks R, Arora V, Spanheimer R. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. J Clin Hypertens (Greenwich). 2010 Dec;12(12):973-82. doi: 10.1111/j.1751-7176.2010.00389.x. Epub 2010 Nov 8. PubMed 21122063 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2008
First posted
Aug 4, 2008
Start
Jun 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Mar 9, 2010
Last update
Jul 29, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00727857
Lead sponsor
Takeda
First posted
Aug 4, 2008
Start date
Jun 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Mar 9, 2010
Last update
Jul 29, 2011

Study contacts

VP Clinical Science Strategy
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Metformin

Start the discussion